Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anticholinergic/sedative combos

Executive Summary

FDA rejects hearing requests and withdraws NDAs for Searle's Pro-Banthine with Phenobarbital and DuPont's Valpin with Phenobarbital. In Sept. 14 Federal Register notice, FDA said firms submitted no new data, but rather "relied on legal arguments," principally that they need more time to conduct studies ant that FDA is required to act on the combos as a class

You may also be interested in...



Pipeline Watch: Phase III Readouts In Alopecia Areata, Cervical Dysplasia, Anaphylaxis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Hyloris Adds Aguettant Deals For Maxigesic IV In Europe

Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.

Execs On The Move: Activity In Board Rolls As AxoGen, Alafair, InfuSystem And Others Appoint New CEOs

Alongside a number of chief executive officer appointments, companies such as Endotronix, TruScreen, Glaukos, and others have appointed new board members. AxoGen and Acutus announced new chief financial officers.

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel